Arcadia Biosciences 3Q 2026: Revenue $1.62M, EPS $0.29 — 10-Q Summary

Arcadia Biosciences reported 3Q 2026 revenue of $1.62M, up 24% YoY, and net income of $1.76M, up 105% YoY. EPS was $0.29, down 53.2% YoY. The company cited strong product volumes and a $2.6M gain from warrant and option liabilities. Costs fell 14% due to a $175K tariff refund. Arcadia expressed doubt about its ability to continue as a going concern.

Original reporting
Published Nov 12, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Arcadia Biosciences 3Q 2026: Revenue $1.62M, EPS $0.29 — 10-Q Summary — source image
Decision brief

The 30-second read

$RKDABearishMed
01

Why it matters

The earnings miss and liquidity warning are likely to depress the stock in the short term, especially given the micro‑cap nature of the company.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; new data but limited market breadth.

03

What to watch

Potential upcoming partnership or licensing deals not disclosed in the filing could mitigate cash concerns.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

Arcadia Biosciences filed its Q3 2026 10‑Q, showing modest revenue growth but a sharp earnings decline and a going‑concern warning.

Company-level read

Ticker impact

$RKDABearishMedium confidence
Context

Arcadia Biosciences reported Q3 2026 revenue of $1.62M and a 53% EPS decline, highlighting cash‑flow concerns and a going‑concern warning.

Expected impact

likely downward pressure as investors price in weaker earnings and liquidity risk

Evidence & confidence

Revenue grew modestly while EPS fell sharply and the company warned of insufficient cash for the next year, a negative catalyst for a micro‑cap.

Market effects

Limited impact on the broader biotech sector; micro‑cap earnings often remain isolated.

Primarily affects U.S. small‑cap investors; no broader regional effect.

Low global relevance due to the company's small size and niche market.

Counterpoint

If the cash‑flow warning is overstated, the stock could rebound on short‑covering.

Key entities

  • Arcadia Biosciences, Inc.

    Biotech firm reporting Q3 2026 results (ticker RKDA).

Related articles

$RKDAMed

Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights -- Zola ® Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 --

$RKDAMed

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights – Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 m

$RKDAMedAI 9/10

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.

$BABAMed

Alibaba and Temu cut marketing as AI engines start handing out coupons

Alibaba and Temu's parent company PDD reduced marketing spending by 38% and 17% respectively, with Alibaba's revenue up 10% and Temu's flat. Both companies shifted focus to AI and advertising. Alibaba's cloud revenue rose 53%, while Temu's advertising income overtook commissions. AI assistants now provide coupon codes directly, potentially impacting coupon sites.